Table 1

Baseline characteristics of patients with and without AHREs

VariableOverall
(n=343)
Patients without AHREs
(n=178)
Patients with AHREs
(n=165)
p Value
Age, years80±780±780±70.38
Male sex167 (49)79 (48)88 (49)0.77
BMI, kg/m223±423±423±40.26
Current smoking32 (9)15 (8)17 (10)0.55
Reason for PMI
 Sinus node disease/AV node disease147/196
(43/57)
46/132
(26/74)
101/64
(61/39)
<0.01
CHADS2 score2.3±1.12.1±1.02.5±1.2<0.01
 (0/1–2/>2)17/200/126
(5/58/37)
12/111/55
(7/62/31)
5/89/71
(3/54/43)
0.03
Comorbidities
 Congestive heart failure56 (16)17 (10)39 (24)<0.01
 Hypertension278 (81)141 (79)137 (83)0.37
 Diabetes mellitus94 (27)49 (28)45 (27)0.96
 Previous stroke/SE/TIA52 (15)21 (12)31 (19)0.07
 Dyslipidaemia136 (40)72 (40)64 (39)0.75
 Chronic kidney disease205 (60)108 (61)97 (59)0.72
 Coronary artery disease38 (11)15 (8)23 (14)0.10
 Cardiomyopathy18 (5)5 (3)13 (8)0.04
  Valvular heart disease35 (10)14 (8)21 (8)0.14
   Mitral valve disease14 (4)5 (3)9 (5)0.22
Prior documented paroxysmal AF82 (24)13 (7)69 (42)<0.01
Echocardiography
 LVEF, %67±967±866±90.31
 LAD, mm41±740±643±7<0.01
Drug prescribed at PMI
 Oral anticoagulant53 (15)7 (4)46 (28)<0.01
 Antiplatelet (including aspirin)113 (33)54 (30)59 (36)0.29
 Class I or III AAD45 (13)9 (5)36 (22)<0.01
  • Date are presented as means±SD or n (%).

  • AAD, antiarrhythmic drug; AF, atrial fibrillation; AHREs, atrial high rate episodes; AV node disease, atrioventricular node disease; BMI, body mass index; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; PMI, pacemaker implantation; SE, systemic embolism; TIA, transient ischaemic attack.